Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Ahead of Print

Successful treatment with durvalumab: A case report and review

 Hospital Pharmacy, Unidad de Gestión Clínica Farmacia, Hospital Juan Ramón Jiménez, Huelva, Spain

Correspondence Address:
Ana Peláez Bejarano,
Unidad de Gestión Clínica Farmacia, Hospital Juan Ramón Jiménez, Ronda Norte S/N, 21005 Huelva
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jcrt.jcrt_1430_21

Stage III non-small-cell lung cancer (NSCLC) represents a heterogeneous group of disease entities with multimodality treatments. For most patients, platinum-based doublet with concurrent chemoradiotherapy (CRT) has become the first-choice treatment over the past decade. Immune checkpoint inhibition has revolutionized the management of metastatic NSCLC; however, no major advances in systemic therapy for Stage III NSCLC have been made. The following report is the case of a patient with unresectable Stage IIIA NSCLC successfully treated with durvalumab. The patient completed 1 year of treatment without interruptions, and disease control has been maintained for more than 20 months since the start of durvalumab.

Print this article
  Search Pubmed for
    -  Bejarano AP
    -  Pérez OM
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded14    

Recommend this journal